Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement: A Case Series
Conclusions:
DOAC therapy after TAVR was generally safe and well tolerated. Taken in context of other retrospective studies, these data suggest that the presence of valvular heart disease, specifically TAVR in this case, should not preclude the use of DOACs.
Source: Journal of Cardiovascular Pharmacology - Category: Cardiology Tags: Original Article Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Coumadin | Databases & Libraries | Drugs & Pharmacology | Heart | Heart Disease | Heart Valve Surgery | Pradaxa | Study | Thrombosis | Warfarin